How to Advertise a GLP-1 Weight Loss Program Legally

Weight loss clinics keep asking the same question in the wrong order. They ask whether they can run ads. The real question is which of three separate rulebooks just disapproved them, because they are not the same rulebook and they do not say the same thing.

The FDA decides what your pharmacy partner may legally compound. Google and Meta decide what you may say and what you may bid on. The FTC decides what results you may promise. A clinic that reads all three correctly can run profitable ads today. A clinic that reads one and guesses the other two gets suspended.

Can you legally advertise a GLP-1 weight loss program?

Yes. A licensed US clinic can advertise a medically supervised weight loss program, and in the United States Google will even let you use prescription drug terms in your ad copy and on your landing page without any certification. What you cannot do is bid on those terms as keywords without certification, name the drug on Meta without a LegitScript certification, or promise a weight number you cannot support with a controlled clinical trial.

That is three different constraints from three different bodies, and clinics constantly collapse them into one imagined rule that says 'you can't mention Ozempic.' That imagined rule is wrong in a way that costs money — it makes operators over-censor their landing pages while under-censoring the two things that actually get accounts killed: keyword targeting and results claims.

Sort your problem into the right bucket before you touch the account. If your ads are getting disapproved and you do not know which of the three is biting, start with the platform layer — the mechanics are the same as any restricted vertical, and the Google Ads fundamentals for service businesses still apply underneath.

What changed when the FDA declared the shortages resolved?

FDA determined the tirzepatide injection shortage was resolved on October 2, 2024, re-confirmed that determination on December 19, 2024, and determined the semaglutide injection shortage was resolved on February 21, 2025. Once a shortage is resolved, the legal cover that let pharmacies mass-produce copies of the drug goes away with it.

The FDA's own compounder timeline is specific about when the door closed. Read it as a business calendar, because that is what it is.

In its April 1, 2026 update, FDA states plainly that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list. That single sentence is what pulled the floor out from under a whole category of $199-a-month telehealth offers.

Two details from that FDA page matter more to your marketing than anything else on it. First, FDA says it does not intend to act against a compounder making essentially-a-copy product if the compounder fills four or fewer prescriptions of that product in a calendar month — that is a per-pharmacy volume ceiling, not a business model. Second, FDA says it may treat a compounded semaglutide-plus-B12 injection as essentially a copy when the route is the same and the strengths are within 10% of the commercially available products. The 'we add B12 so it's a different drug' workaround has an explicit FDA answer, and the answer is no.

Marketing implication: if your $2,500 ad budget is buying leads for an offer priced on unlimited compounded supply, you are buying leads for an offer that can be repriced by a regulatory update you do not control.

What will Google and Meta actually let you say about the drug?

Google and Meta are not aligned, and the gap between them is the single most exploitable fact in this vertical. Google's Restricted drug terms policy states that for campaigns targeting the United States, Canada, or New Zealand, 'you don't need to be certified in order to use prescription drug terms in ads and landing pages, you must be certified in order to keyword-target these terms.' Meta's Drugs and Pharmaceuticals standard allows prescription drug promotion only for advertisers 'actively certified with LegitScript.'

Verdict: Google is the permissive platform and Meta is the strict one, and most clinics have it backwards. They scrub the drug name off a Google landing page where it was legal, then run a Meta ad naming semaglutide with no LegitScript certification, which is the version that actually breaks the rules.

There is a trapdoor under all of this. Google's Prescription drug services policy covers 'the online prescribing, dispensing, and sale of prescription drugs' and says Google 'errs on the side of caution in applying this policy, especially for landing pages that link or refer to content that in any way appears to be or to facilitate the online prescription, dispensation, or sale of medicines.' If your page has a Start My Intake button that ends in a prescription, Google can classify you as a telemedicine advertiser regardless of how careful your headline was, and then you need certification to serve ads at all.

The good news on that policy: Google says violations of it get a warning at least 7 days before suspension. The bad news is a different policy entirely — unauthorized pharmacies — where offering prescription drugs without a prescription or targeting locations you are not licensed in is treated as egregious, and accounts are 'suspended upon detection and without prior warning.' Do not let a growth-hacking contractor near that line.

Meta hands you its own escape hatch in the policy text: advertisers do not need written authorization to run ads that 'promote telehealth services generally.' Generally. That is the whole play — sell the telehealth weight loss program, not the molecule.

How do you write an ad for a service you cannot name?

Sell the program, not the molecule: the headline names the outcome, the supervision, and the price, and never the active ingredient. This is not a compromise. Drug-agnostic copy converts better anyway, because it survives the moment the patient discovers your competitor charges $50 less for the same vial.

The searcher already knows what they want. They typed the drug name into Google or they typed 'weight loss doctor near me' — either way your job is to be the credible, supervised, priced-in-public option. Your ad does not need to say the word to win the click.

On keywords, accept the constraint and route around it. You cannot keyword-target the drug terms without certification, so build the campaign on the drug-agnostic demand that is legal for you today: medical weight loss clinic, physician supervised weight loss, weight loss doctor near me, obesity medicine specialist, weight loss consultation. These convert to booked consults at least as well, and they do not put your account in a certification queue.

Then defend the account with negatives. Strip free, coupon, buy online, no prescription, without doctor, samples, reddit, review, and every competitor brand you are not certified to touch. A GLP-1 account bleeds budget to price-shoppers faster than almost any other vertical — the negative keyword discipline for service businesses is not optional here, it is the difference between a $90 consult and a $400 one.

One thing operators forget: sitelinks, callouts, structured snippets, and your display path are all ad copy. A clean headline with a /semaglutide-pricing display path is still a drug-term ad. Audit the assets, not just the headline.

What does the landing page have to do that the ad cannot?

The landing page carries the four things the ad has no room for — the monthly price, who prescribes and under what license, the eligibility criteria, and the first-90-days sequence — and in the United States that page may name the drug, because Google's non-certified restriction is on keyword targeting, not on landing page text.

That is the asymmetry you build the funnel on. Ad stays drug-agnostic. Page gets specific. The visitor who clicked a 'physician-supervised weight loss' ad lands on a page that tells them exactly what they are getting, in plain language, with a number next to it.

• Price, on the page, above the fold. 'Call for pricing' in a cash-pay category is a bounce.
• Eligibility, stated: BMI thresholds, comorbidities, and who you will turn away. Turning people away is a trust signal.
• Who prescribes: license type and state. Not a stock photo of a lab coat.
• Sourcing, honestly labeled. If any product is compounded, say so — FDA states plainly that compounded drugs are not FDA-approved.
• What is included beyond the injection: labs, titration schedule, side-effect management, nutrition support, monthly visits.
• What happens when you stop, and what the taper looks like. Nobody else answers this, and every prospect is thinking it.

Now the trapdoor again. If that page runs an online intake that ends in a prescription without an in-person encounter, Google can read it as prescription drug services and you need certification to run ads at all. The fix is not to hide the intake — it is to get the certification if that is your model, and to keep the paid landing page focused on booking a consult rather than facilitating a prescription. The rest of the page mechanics are ordinary: the same paid-ads landing page structure that works for service businesses applies, just with a compliance layer on top.

Which weight loss claims survive the FTC substantiation standard?

Almost none of the ones clinics currently use. The FTC's Health Products Compliance Guidance, published December 2022, states that 'substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing to meet the competent and reliable scientific standard.' That means the only pound-and-percentage figures you can safely publish are the ones from the trials behind the FDA-approved drug — attributed, dated, and not stretched.

Testimonials are where the vertical gets itself sued. The FTC guidance is blunt: 'Testimonials that report results more dramatic than users can generally expect are likely to be deceptive,' and 'attempts to disclaim dramatic results with statements like Results not typical don't cure the deception.' A testimonial that beats your typical outcome must be accompanied by a clear and conspicuous disclosure of what a typical consumer can actually expect.

The guidance even walks through a weight loss example: a woman photographed before and after, quoted as losing 16 pounds in eight weeks, with an asterisked fine-print 'These results are not typical' — while the actual controlled trial showed an average of four pounds over placebo in the same window. The FTC's verdict is that the vague disclosure does not adequately convey that a consumer's weight loss is likely to be much less, and that the placement and size of the disclaimer is insufficiently prominent to qualify the claim.

So: before-and-after photos are not banned, they are conditional. Use them only with a typical-results disclosure that a normal person would actually read. And on Google, note that products containing hCG for weight loss are prohibited outright under the unapproved substances policy, regardless of any claim of legality — that is a full stop, not a certification gate.

Aesthetic and cosmetic operators run into the same claim-substantiation wall from a different direction; the med spa compliance and results-claims playbook covers the overlap if you sell both.

How do you qualify a GLP-1 lead before the consult?

A GLP-1 lead is worth a consult slot only if three things are true at once: they meet your clinical eligibility, they can pay the cash price every month, and they are not shopping for the cheapest vial on the internet. Screen for all three before the booking, not during it, or your consult calendar fills with people who will never start.

Price is the cheapest disqualifier you own. Putting the monthly number in the ad and on the page removes the bottom third of the funnel before it costs you a phone call. Clinics resist this because they want the chance to sell. In a cash-pay category with public competitor pricing, the chance to sell is the chance to waste a slot.

• Height and current weight, so BMI eligibility is answered before a human is involved.
• Prior GLP-1 use, and the last dose. A patient mid-titration is a different offer than a new start.
• Cash-pay acknowledgement with the actual monthly number restated on the form.
• Relevant comorbidities and current medications, routed straight to the clinician.
• Preferred start window. 'Just researching' is a nurture lead, not a consult.

Then answer fast. In a 2011 Harvard Business Review study, firms that contacted an online lead within an hour were nearly seven times as likely to qualify that lead — defined as having a meaningful conversation with a key decision maker — as firms that waited just one hour longer, and more than 60 times as likely as firms that waited 24 hours or more. In a category where the prospect has four other clinic tabs open, an hour is already generous.

Report on started patients and program revenue, never on form fills. A GLP-1 funnel can post beautiful cost-per-lead numbers while converting almost nobody to a paying patient, because the drug name attracts researchers. That is the metric we build paid ads management around, and it is the only one that survives a board meeting.

What happens to your funnel if compounded supply disappears?

If your offer is priced on compounded semaglutide, one FDA determination can reprice your entire program overnight — which is exactly what happened between October 2024 and May 2025 when both shortage resolutions and their enforcement-discretion windows expired. Assume it happens again and build so it does not matter.

The structural fix is to make the molecule a line item rather than the value proposition. A program built on supervision, labs, titration, side-effect management, nutrition, and retention can swap what is in the syringe without rewriting a single ad. A program built on 'cheap semaglutide' cannot swap anything, because cheap semaglutide is the whole promise.

• Never put a molecule in an H1, a URL, or a campaign name. A /semaglutide-clinic page is a page you will have to redirect.
• Run a two-tier offer: an FDA-approved branded path and a non-GLP-1 medical weight loss path, so a supply shock costs you one tier, not the business.
• Price the program, not the vial. If the vial is the price, the vial is the product, and you are in a race to zero.
• Track revenue per started patient and 90-day retention. A channel that produces neither gets cut — we run a 90-day kill switch on every channel for exactly this reason.

Clinics that already rank for drug-agnostic demand ride this out. Clinics that bought their entire pipeline on a molecule name spend the next quarter rebuilding. If you sell into aesthetics or wellness alongside this, the organic side of the same problem is covered on our med spa SEO page.

If your GLP-1 ads are disapproved, your cost per started patient is unknown, or your whole offer is one FDA update away from repricing, that is a paid-media structure problem, not a copywriting problem. We build drug-agnostic acquisition funnels for cash-pay clinics — paid ads management, month-to-month, no lock-in, and you own the account. Get my free audit.